Theraclion

Theraclion, founded in 2004, is a groundbreaking French MedTech company specializing in non-invasive solutions for varicose vein treatment. Renowned for its product Sonovein®, Theraclion uses High Intensity Focused Ultrasound (HIFU) in a robotic-driven platform that eliminates the need for surgical incisions and reduces recovery time for patients. This CE-marked innovation has the potential to significantly disrupt traditional surgical methods, promising to replace millions of procedures annually.

Based in Malakoff, with a dedicated team of 30, primarily in technological and clinical development, Theraclion is positioned in industries like Biotechnology, Health Care, Manufacturing, and Medical Devices. Their last funding was a €1.50M Post-IPO Debt investment on 20 February 2025. However, the Sonovein® is still under investigational use in the U.S. market, offering significant growth potential upon regulatory approval.